GlobeStar Therapeutics (GlobeStar Therapeutics) Cash-to-Debt : 0.00 (As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is GlobeStar Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. GlobeStar Therapeutics's cash to debt ratio for the quarter that ended in Dec. 2023 was 0.00.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, GlobeStar Therapeutics couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for GlobeStar Therapeutics's Cash-to-Debt or its related term are showing as below:

During the past 13 years, GlobeStar Therapeutics's highest Cash to Debt Ratio was 1.34. The lowest was 0.00. And the median was 0.27.

GSTC's Cash-to-Debt is not ranked ^*
in the Biotechnology industry.
Industry Median: 6.89
* Ranked among companies with meaningful Cash-to-Debt only.

GlobeStar Therapeutics Cash-to-Debt Historical Data

The historical data trend for GlobeStar Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

GlobeStar Therapeutics Cash-to-Debt Chart

GlobeStar Therapeutics Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Cash-to-Debt

Get a 7-Day Free Trial

0.88

0.52

0.30

GlobeStar Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															0.40	N/A	-	-	-

Competitive Comparison of GlobeStar Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, GlobeStar Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GlobeStar Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GlobeStar Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where GlobeStar Therapeutics's Cash-to-Debt falls into.

GlobeStar Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

GlobeStar Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Sep. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0	/	(0.36	+	0)
	=	0.00

GlobeStar Therapeutics's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0	/	(0.369	+	0)
	=	0.00

GlobeStar Therapeutics (OTCPK:GSTC) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

GlobeStar Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of GlobeStar Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

GlobeStar Therapeutics (GlobeStar Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GlobeStar Therapeutics Corp (OTCPK:GSTC) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

719 Jadewin Avenue, Richland, WA, USA, 99352

Website

https://www.globestarthera.com

GlobeStar Therapeutics Corp is a clinical-stage Pharmaceutical Company introducing a patented formulation of previously approved drugs for the treatment of Multiple Sclerosis. The company is focused on developing therapies for people with serious and life-threatening rare disorders.

Executives

James C Katzaroff	director, officer: CEO	719 JADWIN AVE., RICHLAND WA 99352
William J Farley	director	468 ALBERN AVE, OCEANSIDE NY 11572
Robert Chicoski	officer: CFO	145 NEWTON ROAD, HAVERHILL MA 01830
Alex K Blankenship	director, officer: CEO, Pres., Secr., Treas.	14001 WALDEN RD., SUITE 600, MONTGOMERY TX 77356
Brent Atwood	10 percent owner	5000 RIVERSIDE DR STE100E, IRVING TX 75039
Bruce C Badeau	director	770 S. POST OAK LN., STE. 360, HOUSTON TX 77056
Robert W Fryer	director	1520 ENCLAVE, # 1208, HOUSTON TX 77077
Robert Federowicz	director, officer: Interim CEO & Chairman	495 GRAND BLVD., SUITE 206, MIRAMAR BEACH FL 32550